196 related articles for article (PubMed ID: 18383741)
21. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Semin Radiat Oncol; 2007 Jul; 17(3):223-9. PubMed ID: 17591569
[TBL] [Abstract][Full Text] [Related]
22. Primary central nervous system lymphoma report of 32 cases and review of the literature.
Dubuisson A; Kaschten B; Lénelle J; Martin D; Robe P; Fassotte MF; Rutten I; Deprez M; Stevenaert A
Clin Neurol Neurosurg; 2004 Dec; 107(1):55-63. PubMed ID: 15567554
[TBL] [Abstract][Full Text] [Related]
23. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Neurol Clin; 2007 Nov; 25(4):1193-207, xi. PubMed ID: 17964031
[TBL] [Abstract][Full Text] [Related]
24. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.
Schulz H; Pels H; Schmidt-Wolf I; Zeelen U; Germing U; Engert A
Haematologica; 2004 Jun; 89(6):753-4. PubMed ID: 15194546
[TBL] [Abstract][Full Text] [Related]
25. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
26. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia.
Erkurt MA; Aydogdu I; Kuku I; Kaya E; Basaran Y
Med Princ Pract; 2009; 18(5):399-406. PubMed ID: 19648764
[TBL] [Abstract][Full Text] [Related]
28. Primary CNS lymphoma in immunocompetent patients.
Sierra del Rio M; Rousseau A; Soussain C; Ricard D; Hoang-Xuan K
Oncologist; 2009 May; 14(5):526-39. PubMed ID: 19433528
[TBL] [Abstract][Full Text] [Related]
29. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.
Olson JE; Janney CA; Rao RD; Cerhan JR; Kurtin PJ; Schiff D; Kaplan RS; O'Neill BP
Cancer; 2002 Oct; 95(7):1504-10. PubMed ID: 12237919
[TBL] [Abstract][Full Text] [Related]
30. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
31. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
Levy O; Deangelis LM; Filippa DA; Panageas KS; Abrey LE
Cancer; 2008 Jan; 112(1):151-6. PubMed ID: 17999414
[TBL] [Abstract][Full Text] [Related]
32. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
Vranovsky A; Ladicka M; Lakota J
Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of primary central nervous system lymphoma in the immunocompetent patient].
Sierra Del Rio M; Benouaich-Amiel A; Psimaras D; Dehais C; Hoang-Xuan K
Rev Neurol (Paris); 2008; 164(6-7):569-74. PubMed ID: 18565356
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
36. Primary CNS lymphoma.
Batchelor T; Loeffler JS
J Clin Oncol; 2006 Mar; 24(8):1281-8. PubMed ID: 16525183
[TBL] [Abstract][Full Text] [Related]
37. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
[TBL] [Abstract][Full Text] [Related]
38. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.
Salvesen Haldorsen I; Aarseth JH; Hollender A; Larsen JL; Espeland A; Mella O
Acta Oncol; 2004; 43(6):520-9. PubMed ID: 15370608
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system lymphoma.
Stern JI; Raizer JJ
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S63-70. PubMed ID: 16274272
[TBL] [Abstract][Full Text] [Related]
40. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
